Cytori Therapeutics Inc. (NASDAQ:CYTX) fell 2.4% during mid-day trading on Tuesday . The company traded as low as $2.03 and last traded at $2.03, with a volume of 58,328 shares traded. The stock had previously closed at $2.08.

A number of brokerages have recently issued reports on CYTX. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the stock a “buy” rating in a report on Friday, August 5th. Roth Capital restated a “buy” rating and set a $11.00 price objective on shares of Cytori Therapeutics in a report on Tuesday, June 28th. Finally, Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Tuesday, July 12th.

The stock has a 50 day moving average price of $2.09 and a 200 day moving average price of $2.69. The stock’s market capitalization is $41.60 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cytori Therapeutics (NASDAQ:CYTX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.04. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $2.50 million. Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 203.79%. Cytori Therapeutics’s revenue for the quarter was down 31.3% compared to the same quarter last year. During the same period last year, the company earned ($0.06) EPS. On average, equities analysts expect that Cytori Therapeutics Inc. will post ($1.29) EPS for the current year.

A hedge fund recently bought a new stake in Cytori Therapeutics stock. Cambridge Associates LLC MA ADV purchased a new stake in shares of Cytori Therapeutics Inc. (NASDAQ:CYTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,000 shares of the company’s stock, valued at approximately $852,000. Cytori Therapeutics accounts for about 0.4% of Cambridge Associates LLC MA ADV’s portfolio, making the stock its 19th largest position. 18.48% of the stock is currently owned by hedge funds and other institutional investors.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

5 Day Chart for NASDAQ:CYTX

Receive News & Ratings for Cytori Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc. and related companies with's FREE daily email newsletter.